Company intelligence / Profile preview

Altris AI

Chicago, Illinois, United Statesaltris.ai ↗

Ownership: Private
Employees: ~30
Development stage: Commercial

Overview

The Altris AI platform has been trained on over five million OCT scans. It automates the detection of more than seventy retinal pathologies and biomarkers, supports glaucoma risk assessment, provides quantitative biomarker analysis for disease progression monitoring, and has received both FDA clearance and CE certification. The system is vendor-neutral—compatible with all OCT devices—and used by hundreds of clinics worldwide. No clinical trial results are reported as it’s a diagnostic support tool rather than a therapeutic intervention.

Therapeutic areas: Ophthalmology
Modalities: Device (AI-powered diagnostic software)
Industry: Medical Imaging

Partnerships

Topcon HealthcareOptopolHuvitz Corporation

Beyond the preview

Go deeper on Altris AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altris AI.

Explore the full profile